Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

This study has been completed.
Information provided by (Responsible Party):
FORUM Pharmaceuticals Inc Identifier:
First received: August 3, 2012
Last updated: January 10, 2014
Last verified: January 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)